Disc Medicine Set To Report Phase 3 Bitopertin Results In Rare Blood Disorder; Stock Up
(RTTNews) - Disc Medicine, Inc. (IRON) is scheduled to release topline results today from the Phase 3 APOLLO trial evaluating Bitopertin in patients with erythropoietic protoporphyria (EPP), a rare inherited blood disorder. The company will discuss the findings during a corporate
